| Literature DB >> 34588477 |
Tetsuya Ito1,2, Emi Tomizawa3, Yuki Yano3, Kiyozumi Takei3, Naoko Takahashi3, Fumio Shaku4.
Abstract
Various physical and psychosocial difficulties including anxiety affect cancer patients. Patient surroundings also have psychological effects on caregiving. Assessing the current status of palliative care intervention, specifically examining anxiety and its associated factors, is important to improve palliative care unit (PCU) patient quality of life (QOL). This study retrospectively assessed 199 patients admitted to a PCU during August 2018-June 2019. Data for symptom control, anxiety level, disease insight, and communication level obtained using Support Team Assessment Schedule Japanese version (STAS-J) were evaluated on admission and after 2 weeks. Palliative Prognostic Index (PPI) and laboratory data were collected at admission. Patient anxiety was significantly severer and more frequent in groups with severer functional impairment (p = 0.003) and those requiring symptom control (p = 0.006). Nevertheless, no relation was found between dyspnea and anxiety (p = 0.135). Patients with edema more frequently experienced anxiety (p = 0.068). Patient survival was significantly shorter when family anxiety was higher after 2 weeks (p = 0.021). Symptoms, edema, and disabilities in daily living correlate with patient anxiety. Dyspnea is associated with anxiety, but its emergence might be attributable mainly to physical factors in this population. Family members might sensitize changes reflecting worsened general conditions earlier than the patients.Entities:
Mesh:
Year: 2021 PMID: 34588477 PMCID: PMC8481243 DOI: 10.1038/s41598-021-97143-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patient characteristics.
| (A) Patient background | Mean ± SD (median; range) or number (%) | |
|---|---|---|
| Age (y.o.) | 199 | 70.9 ± 12.7 (72; 18–97) |
| Sex | 199 | Male, 87 (43.7)/ Female, 112 (56.3) |
| Primary site | 199 | Lung, 40 (20.1) / Pancreas, 32 (16.1) / Colorectal, 20 (10.5) / Gastric (including 1 GIST), 19 (9.5) / Hepatobiliary, 18 (9.0) / Breast, 15 (7.5) / Hematological, 10 (5.0) / Oral and Maxillofacial, 9 (4.5) / Esophagus, 7 (3.5) / Uterine, 5 (2.5) / Ovary, 4 (2.0) / Thyroid, 3 (1.5) / Prostate, 3 (1.5) / Cerebral, 2 (1.0) / Thymus, 2 (1.0) / Cecum, 2 (1.0) / Pleural mesothelioma, 1 (0.5) / Renal, 1 (0.5) / Renal pelvis, 1 (0.5) / Testicular, 1 (0.5) / Others, 3 (1.5) / Unknown, 1 (0.5) |
Patient anxiety on admission by symptom control.
| Pain and Other symptoms | Patient anxiety on admission | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | |||||||
Both < 2 Symptom under control | 4 (11.8%) | 26 (76.5%) | 3 (8.8%) | 1 (2.9%) | 0 (0.0%) | 34 (100.0%) | |||||
Others Symptom control required | 3 (3.6%) | 53 (63.1%) | 17 (20.2%) | 9 (10.7%) | 2 (2.4%) | 84 (100.0%) | |||||
| Total | 7 (5.9%) | 79 (66.9%) | 20 (16.9%) | 10 (8.5%) | 2 (1.7%) | 118 (100.0%) | |||||
p = 0.006* (Wilcoxon rank sum test).
Inflammatory markers and patient anxiety evaluated with STAS-J on Admission.
| Laboratory test | Patient anxiety ≥ 2 | Patient anxiety < 2 | Wilcoxon rank sum test ( | ||||
|---|---|---|---|---|---|---|---|
| Mean ± SD | (Median; range) | Mean ± SD | (Median; range) | ||||
| WBC (× 103/μL) | 10.0 ± 5.5 | (8.2; 3.1–24.8) | 26 | 9.5 ± 6.2 | (8.3; 2.7–42.9) | 68 | 0.660 |
| Ly (%) | 10.4 ± 9.4 | (8.3; 2.0–36.0) | 22 | 11.0 ± 8.3 | (7.9; 1.0–50.7) | 62 | 0.445 |
| CRP (mg/dL) | 6.1 ± 6.5 | (4.5; 0.4–26.9) | 26 | 6.7 ± 6.5 | (4.6; 0.0–32.5) | 68 | 0.507 |
Anxiety of patients evaluated with STAS-J and PPI.
| 0 | 1 | 2 | 3 | 4 | Total | ||
|---|---|---|---|---|---|---|---|
| PPI total score | ≤ 6.0 | 7 (8.9%) | 50 (63.3%) | 15 (19%) | 6 (7.6) | 1 (1.3%) | 79 (100.0%) |
| > 6.0 | 1 (2.9%) | 24 (70.6%) | 4 (11.8%) | 4 (11.8%) | 1 (2.9%) | 34 (100.0%) | |
| Total | 8 (7.1%) | 74 (65.5%) | 19 (16.8%) | 10 (8.8%) | 2 (1.8%) | 113 (100.0%) | |
| PPI total score | ≤ 4.0 | 5 (11.9%) | 26 (61.9%) | 7 (16.7%) | 3 (7.1%) | 1 (2.4%) | 42 (100.0%) |
| > 4.0 | 3 (4.2%) | 48 (67.6%) | 12 (16.9%) | 7 (9.9%) | 1 (1.4%) | 71 (100.0%) | |
| Total | 8 (7.1%) | 74 (65.5%) | 19 (16.8%) | 10 (8.8%) | 2 (1.8%) | 113 (100.0%) | |
| PPI-PPS | 0 | 4 (33.3%) | 7 (58.3%) | 1 (8.3%) | 0 (0.0%) | 0 (0.0%) | 12 (100.0%) |
| 2.5 | 3 (3.3%) | 59 (64.8%) | 18 (19.8%) | 9 (9.9%) | 2 (2.2%) | 91 (100.0%) | |
| 4.0 | 1 (6.7%) | 13 (86.7%) | 0 (0.0%) | 1 (6.7%) | 0 (0.0%) | 15 (100.0%) | |
| Total | 8 (6.8%) | 79 (66.9%) | 19 (16.1%) | 10 (8.5%) | 2 (1.7%) | 118 (100.0%) | |
| PPI-Oral intake | 0 | 3 (11.5%) | 18 (69.2%) | 3 (11.5%) | 2 (7.7%) | 0 (0.0%) | 26 (100.0%) |
| 1.0 | 4 (6.9%) | 34 (58.6%) | 13 (22.4%) | 5 (8.6%) | 2 (3.4%) | 58 (100.0%) | |
| 2.5 | 1 (2.9%) | 27 (77.1%) | 4 (11.4%) | 3 (8.6%) | 0 (0.0%) | 35 (100.0%) | |
| Total | 8 (6.7%) | 79 (66.4%) | 20 (16.8%) | 10 (8.4%) | 2 (1.7%) | 119 (100.0%) | |
| PPI-Edema | 0 | 5 (9.3%) | 38 (70.4%) | 9 (16.7%) | 1 (1.9%) | 1 (1.9%) | 54 (100.0%) |
| 1.0 | 3 (4.9%) | 38 (62.3%) | 10 (16.4%) | 9 (14.8%) | 1 (1.6%) | 61 (100.0%) | |
| Total | 8 (7.0%) | 76 (66.1%) | 19 (16.5%) | 10 (8.7%) | 2 (1.7%) | 115 (100.0%) | |
| PPI-Dyspnea | 0 | 8 (8.3%) | 64 (66.7%) | 16 (16.7%) | 7 (7.3%) | 1 (1.0%) | 96 (100.0%) |
| 3.5 | 0 (0.0%) | 15 (65.2%) | 4 (17.4%) | 3 (13.0%) | 1 (4.3%) | 23 (100.0%) | |
| Total | 8 (6.7%) | 79 (66.4%) | 20 (16.8%) | 10 (8.4%) | 2 (1.7%) | 119 (100.0%) | |
| PPI-Delirium | 0 | 7 (6.5%) | 70 (65.4%) | 19 (17.8%) | 9 (8.4%) | 2 (1.9%) | 107 (100.0%) |
| 4.0 | 1 (10.0%) | 7 (70.0%) | 1 (10.0%) | 1 (10.0%) | 0 (0.0%) | 10 (100.0%) | |
| Total | 8 (6.8%) | 77 (65.8%) | 20 (17.1%) | 10 (8.5%) | 2 (1.7%) | 117 (100.0%) | |
(A) p = 0.630 (Wilcoxon rank sum test).
(B) p = 0.429 (Wilcoxon rank sum test).
(C) p = 0.003* (Kruskal–Wallis test).
(D) p = 0.274 (Kruskal–Wallis test).
(E) p = 0.068 (Wilcoxon rank sum test).
(F) p = 0.135 (Wilcoxon rank sum test).
(G) p = 0.559 (Wilcoxon rank sum test).
Figure 1Patient survival and symptom control on admission. No significant relation was found between patient survival and the existence of any symptom requiring control defined by STAS-J: pain or other symptom control ≥ 2 with symptoms, median 21.0 days, n = 110 and without symptoms, median 23.0 days, n = 52, p = 0.313).
Figure 2Patient survival and anxiety. (A) Anxiety of patients. No significant relation was found between patient survival and anxiety of patients on admission and after 2 weeks of admission: p = 0.624 and 0.678 respectively. Higher anxiety is defined as STAS-J: anxiety ≥ 2. (B) Anxiety of families. On admission, no significant difference was found in survival time between groups with and without higher anxiety of families defined as STAS-J anxiety ≥ 2: with, median 18.0 days, n = 30; without, median 17.0 days, n = 84; p = 0.652. However, significantly shorter survival was found when anxiety of family members was higher after 2 weeks: with higher anxiety, median 29.0 days, n = 11; without, median 44.0 days, n = 41; p = 0.021.